Okami Medical has revealed the expansion of its LOBO vascular occlusion system product line with US Food and Drug Administration (FDA) 510(k) clearance of the LOBO-5 vascular occluder.
According to a press release from the company, the LOBO (Low-profile braided occluder) system is uniquely designed to provide interventional physicians with a single-device, “one-and-done” solution for the occlusion of a wide range of peripheral arterial targets. The LOBO system combines neurovascular-derived HDBRAID technology with a patented design to create a highly occlusive structure for fast and efficient closure of blood vessels throughout the body.
LOBO-5, the second offering in the company’s product portfolio, is intended for use in 3–5mm diameter vessels. LOBO-3, the company’s first occluder, is intended for use in 1.5–3mm vessels.
“The FDA clearance of LOBO-5 marks another milestone in our mission to provide patients and physicians with access to advanced technologies that address the numerous unmet clinical needs in peripheral vascular occlusion,” said Bob Rosenbluth, president and CEO of Okami Medical.
He continued: “LOBO-3 and LOBO-5, to be followed by LOBO-7 and LOBO-9, are designed and built to enable fast, predictable and complete occlusion of a diverse set of vascular targets without the need for multiple embolic devices.”
Tin tức liên quan
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389